DNA and DNA replication machinery (DNA)

DNA and the DNA replication machinery represent a broad class of therapeutic targets essential for cellular division and the maintenance of genetic integrity. This target group includes the genomic DNA template itself and the enzymatic assembly known as the replisome, which comprises DNA polymerases, helicases, primases, and topoisomerases [NIH]. In clinical practice, these targets are primarily exploited in oncology to arrest the growth of rapidly proliferating malignant cells by inducing DNA damage or inhibiting synthesis [StatPearls]. For example, alkylating agents form covalent bonds with DNA to prevent replication, while antimetabolites interfere with the availability of nucleotide building blocks [PubChem]. Furthermore, many antimicrobial and antiviral therapies achieve selectivity by targeting structural differences between human and pathogen replication enzymes, such as bacterial DNA gyrase or viral DNA polymerases [PubMed]. Because DNA synthesis is a fundamental biological process, drugs hitting these targets often exhibit a narrow therapeutic index, leading to characteristic toxicities in healthy, fast-dividing tissues like the bone marrow and intestinal epithelium [NIH]. Monitoring biomarkers like Ki-67 or specific DNA repair deficiencies can help predict therapeutic response and manage safety [NCI].

Other names

DNA synthesis apparatusReplisomeDeoxyribonucleic acidDNA replication complexDNA synthesis machinery

The mechanism of action involves the direct modification of the DNA template through alkylation or intercalation, the competitive or non-competitive inhibition of DNA polymerase enzymes, the depletion of essential nucleotide pools, or the stabilization of topoisomerase-DNA cleavage complexes to induce lethal double-strand breaks [StatPearls, PubMed, NIH].